2016 – iCo Therapeutics

CLARIFICATION iCo Therapeutics Announces Positive Study Results and Significant Advances related to Oral Amphotericin B Program

November 28, 2016, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)

ico_admin2019-07-04T03:13:41+00:00November 28th, 2016|2016|

November 24, 2016, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)

ico_admin2019-07-04T03:10:40+00:00November 24th, 2016|2016|

November 15, 2016, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)

ico_admin2019-07-04T03:08:27+00:00November 15th, 2016|2016|

August 19, 2016, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX‐V: ICO)

ico_admin2019-07-04T03:06:44+00:00August 19th, 2016|2016|

June 27, 2016, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)

ico_admin2019-07-04T03:03:33+00:00June 27th, 2016|2016|

April 14, 2016, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)

ico_admin2019-07-04T02:57:31+00:00April 14th, 2016|2016|

February 17, 2016, Vancouver, Canada — iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V:

ico_admin2019-07-04T02:55:11+00:00February 17th, 2016|2016|

January 18, 2016, Vancouver, Canada — iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V:

ico_admin2019-07-04T02:53:12+00:00January 18th, 2016|2016|